Table 1: Summary of published studies on transplantation in ATLL

From: Hematopoietic SCT for adult T-cell leukemia/lymphoma: a review

ReferenceNAge, years (mean)Gender (F/M; N/N)Subtype (N)Donor type (N)Donor HLTV1 serological status (N)Disease status at diagnosis (N)Stem cell source (N)Acute GVHD prophylaxis (N)Conditioning (N)Median time to neutrophil recovery (days)Acute GVHD % (I and II/III and IV)Chronic GVHD %TRM (N)Median OSMedian PFS (%)Relapse rate (%)NRM rate (%)
Tsukasaki et al.22133FAcuteAutoNACRBMNACy+VP16+ ranimustinNANANA114 daysNA0100
Ogata et al.37151FAcuteUDNArDBMCSA+MTXCy+TBI1801001>16 monthsNA00
Tajima et al.38147MAcuteRDNegativerDBMCSA+MTXCy+MCNU+TBINA000>24 monthsNA00
Obama et al.36238, 331/1Acute (1)
Chronic (1)
RD (2)Positive (1)
Negative (1)
CR (2)BM (2)CSA+MTX (2)Cy+TBINA0100014 months, >18 monthsNA500
Borg et al.5141FAcuteRDNegativeCRBMCSA+MTXCy+daunorubicin +TBI18000>23 monthsNA00
Yonekura et al.302137–6213/8Acute (18)
Lymphoma (2)
Chronic (1)
RD (14)
UD (7)
NACR (7)
PR (1)
rD (13)
BM (5)
PB (14)
UCB (2)
CSA+MTX
TCR+MTX
NANA39 (34/5)NA633.2±10.9 at 3 yearsNA4728
Tanosaki et al.291450–649/5Acute (10)
Lymphoma (4)
RD (14)
UD (7)
Positive (7)
Negative (7)
CR (4)
PR (10)
NDCSAFlu+Bu1186 (64/22)71336 at 3 years31 at 3 years4321
Shiratori et al.321541–663/12Acute (6)
Lymphoma (8)
Chronic (1)
RD (10)
UD (5)
Positive (2)
Negative (13)
CR (9)
PR (5)
rD (1)
BM (8)
PB (4)
BM+PB (3)
CSA+MTX (11)
TCR+MTX (4)
Cy+VP16+TBI (5)
Flu+Bu+TBI (5)
Flu+Mel+ TBI (5)
175366273.3 at 3 years67at 3 years713
Miyamura et al.34125FAcuteRDPositivePRPBCSA+MTXCy+TBI15000NANA00
Utsunomiya et al.271033–517/3Acute (8)
Lymphoma (1)
Other (1)a
RD (9)
UD (1)
Negative (7)
Positive (3)
CR (4)
PR (5)
rD (1)
BM (8)
PB (1)
BM+PB (1)
CSA+MTX (9)
TCR (1)
TBI1460 (40/20)40540±10 at 10 years17.5 months2040
Nakase et al.35845–592/6Acute (5)
Lymphoma (3)
RD (3)
UD (5)
Positive (0)
Negative (8)
CR (6)
rD (2)
NDCSA+MTX (5)
TCR+MTX (3)
Cy+TBI (5)
Flu+Bu+TBI (2)
Flu+Mel (1)
NA87 (87/037320 months16.5 months1225
Kami et al.331115–597/4Acute (5)
Lymphoma (4)
Chronic (2)
RD (10)
UD (1)
Negative (9)
Positive (2)
CR (6)
PR (1)
rD (4)
BM (7)
PB (3)
BM+PB (1)
CSA+MTXTBI based (8)
Cy+Bu (1)
Flu+Cy± ATG (2)
114527754.5±30 at 1 year45±30 at 1 year064
Fukushima et al.294028–5322/18Acute (30)
Lymphoma (10)
RD (32)
UD (8)
Negative (27)
Positive (9)
ND (4)
CR (15)
PR (13)
rD (12)
BM (21)
PB (19)
CSA+MTX (28)
TCR+MTX (11)
TCR (1)
TBI based (22)
Bu based (17)
Mel based (1)
1565 (48/17)371745.3 (31.8–58.8) at 3 years33.8 (17.2–49.4) at 3 years2542
Kato et al.313324–5918/15Acute (20)
Lymphoma (7)
ND (6)
UD (33)Negative (33)
Positive (0)
CR+PR (15)
rD (14)
ND (4)
BM (33)CSA+MTX (13)
TCR+MTX (20)
TBI based (22)NA76 (61/15)129a49.5 (31.2–78.5) at 1 year49.2 (33.6–72.1) at 1 year1527
Okamura et al.281651–679/7Acute (11)
Lymphoma (5)
RD (16)Negative (8)
Positive (8)
CR (3)
PR (10)
RD (3)
PB (16)CSAFlu+Bu+ATGNA63 (31/32)37433.3±12.2 at 5 years20±10.3 at 2 years5625
Sobue et al.23143MAcuteRDNegativerDBMMTXCy+TBI200017NA0100
  1. Abbreviations: F=female; HTLV-1=human T-cell lymphotropic virus type 1; M=male; Mel=melphalan; NA=not available; NRM=non-relapse mortality; PB=peripheral blood; RD=related donor; rD=recurrent disease; TCR=tacrolimus; UD=unrelated donor; VP16=etoposide.
  2. aCause of death unknown in three cases.